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Myocardial infarcts are wounds inﬂicted by ischemic injury of
the heart muscle. As in any other wound, a sufﬁcient healing
process after acute injury is prerequisite to the recovery and
integrity of the organ’s function. If infarct healing derails,
ﬁbrosis may be insufﬁcient or too widespread, either endan-
gering the left ventricle’s geometry or increasing its stiffness,
especially if ﬁbrosis occurs in the remote myocardium. The
imminent threat of insufﬁcient healing is a weak scar that may
rupture, often a deadly complication. More frequently, the weak
infarct scar acutely maintains the ventricle’s integrity but ex-
pands over time, thus causing chronic post-myocardial in-
farction (MI) remodeling and heart failure. Macrophages are
centrally involved in wound healing, including healing of the
heart (1). These cells are also part of the causal pathology
leading to ischemia of the heart because macrophages
destabilize atherosclerotic plaques, rendering them prone
to rupture (1).See page 1890These insights have formed our current view of athero-
sclerosis as a chronic inﬂammatory disease, and we are
beginning to understand that plaques and infarcts are not
isolated local events but rather local manifestations of
systemic disease, caused by, among other risk factors, hy-
percholesterolemia and overproduction of leukocytes in the
bone marrow (1). One consequence of the leukocytosis that
occurs in progressive atherosclerosis is the increased avail-
ability of inﬂammatory monocytes, macrophage progeni-
tors, in circulation. In the presence of atherosclerosis, the
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impairing cardiac healing. This has been modeled by
inducing MI in Apoe-/- mice with atherosclerosis (2).
Leukocytosis predicts higher infarct mortality and occur-
rence of heart failure in patients (3,4). Defunct resolution of
inﬂammation in the infarct due to oversupply of inﬂam-
matory cells is a likely cause for these ﬁndings. The transi-
tion from the initial inﬂammatory wound-healing phase,
dominated by inﬂammatory neutrophils, monocytes, and
M1 macrophages, to the inﬂammation resolution phase,
dominated by M2 macrophages, may be delayed or impaired
in many patients. Thus, the typical functions pursued by M2
macrophages during repair could be insufﬁcient. These
include putative macrophage instruction of resident cells,
including myocytes, endothelial cells forming neovessels,
and ﬁbroblasts that supply the new extracellular matrix, that
provides a durable scar and resists the mechanic forces in the
heart (5). Increasingly, it is believed that the transition of
macrophage polarization from the classical M1 toward
a lesser inﬂammatory M2 phenotype is a key event in infarct
repair (1,6).
The stem cell ﬁeld started out with the goal of restoring
the integrity of the infarcted left ventricle. The hope is that
someday the myocytes that died because of ischemia can be
replaced by progenitors that give rise to new myocytes (7).
Current candidate cells are cardiac progenitors that naturally
occur in the heart and can be harvested, multiplied, and
reinjected (8), as well as inducible pluripotent stem cells
(iPS), which are reprogrammed from differentiated lineages,
for instance, skin ﬁbroblasts (9). An exciting new avenue is
in situ reprogramming of ﬁbroblasts into myocytes (10), but
this technology is still in its infancy. Nevertheless, many pre-
clinical and clinical trials reported beneﬁcial effects of stem
cell therapy on infarct healing, despite lack of evidence for
stem cell survival after transplantation into the heart and the
cell’s failure to give rise to new functional myocytes. Many
in the ﬁeld assigned the observed beneﬁts to paracrine
effects of transplanted cells. The study by Ben-Mordechai
et al. (11) in this issue of the Journal provides an insightful
explanation of how mesenchymal stromal cell (MSC) in-
jection could positively affect infarct healing by crosstalk
between injected stem cells and macrophages (Fig. 1).
The investigators conﬁrm the previously reported (12,13)
biphasic myeloid cell response after acute MI. Using ﬂow
cytometry, they describe an early dominance of inﬂamma-
tory M1 macrophages followed by abundance of M2
macrophages on day 7 after ischemic injury. Interestingly,
injection of MSC reshaped the macrophage response by
favoring M2 polarization. The MSC injection increased the
numbers of M2 macrophages as compared to saline or bone
marrow mononuclear cell injection. The treatment further
changed the cytokine proﬁle of macrophages (e.g., more
interleukin-10 production) and increased the elaboration of
macrophage-derived factors involved in wound healing,
including vascular endothelial growth factor and platelet
factor-4. Proteolytic cathepsin activity was reduced by MSC
Figure 1 Modulation of Macrophage Polarization by MSC Injection
The key ﬁnding of Ben-Mordechai et al. (11) is the modulation of macrophage polarization by mesenchymal stroma cell (MSC) injection. If macrophages are depleted, the positive
effects of MSC treatment are lost.
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1903treatment, which may change the post-MI balance of matrix
production and its digestion by proteases (14), favoring
infarct stability. The MSC treatment further improved
regional myocardial function as measured with speckle
tracking strain echocardiography and attenuated post-MI
heart failure.
When Ben-Mordechai et al. (11) depleted macrophages
with clodronate liposomes, the beneﬁcial effects of MSC
treatment were lost. The 30-day mortality was worse and
infarct size increased. Macrophage depletion accelerated LV
remodeling, resulting in larger hearts and a lower ejection
fraction. Of note, clodronate liposomes can likely deplete
inﬂammatory and noninﬂammatory subsets of monocyte
and macrophages. Nevertheless, these data imply that
positive effects of stem cell therapy may arise from the
inﬂuence of stem cells on macrophage polarization in the
wound. Stem cell therapy may usher in resolution of
inﬂammation and support the salutary effects of M2
macrophages during healing.
Interesting open questions remain: how do MSC change
macrophage polarization? Is it facilitated through direct
cell-cell contact? Do MSC provide speciﬁc cytokines that
inﬂuence macrophage polarization? Answering these
questions may require directly observing MSC-macrophage
crosstalk using intravital microscopy of infarcted hearts
(15). If there is a deﬁned MSC-derived factor that acts on
wound healing and on infarct macrophages, its discovery
may augment pharmacologic, namely, cell-independent
treatment of infarct healing. Another interesting question
is whether MSC-macrophage crosstalk is unidirectional or
whether macrophages “talk back,” namely, whether there is
reversed signaling. It is conceivable that macrophages also
inﬂuence rare autologous cardiac progenitor cells, or
injected stem cells, as they do with the more numerousprogenitors of ﬁbroblasts and endothelial cells that take
up residence in acute infarcts. Recent macrophage deple-
tion experiments in salamanders, which regrow limbs af-
ter amputation, showed that limb regeneration dependedon
an intact macrophage repertoire (16), suggesting macrophage-
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